Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion

BMC Cancer. 2019 Apr 11;19(1):346. doi: 10.1186/s12885-019-5509-4.

Abstract

Background: Prostate cancer is the most common form of cancer in males and accounts for high cancer related deaths. Therapeutic advancement in prostate cancer has not been able to reduce the mortality burden of prostate cancer, which warrants further research. FRG1 which affects angiogenesis and cell migration in Xenopus, can be a potential player in tumorigenesis. In this study, we investigated the role of FRG1 in prostate cancer progression.

Methods: Immunohistochemistry was performed to determine FRG1 expression in patient samples. FRG1 expression perturbation was done to investigate the effect of FRG1 on cell proliferation, migration and invasion, in DU145, PC3 and LNCaP cells. To understand the mechanism, we checked expression of various cytokines and MMPs by q-RT PCR, signaling molecules by western blot, in FRG1 perturbation sets. Results were validated by use of pharmacological inhibitor and activator and, western blot.

Results: In prostate cancer tissue, FRG1 levels were significantly reduced, compared to the uninvolved counterpart. FRG1 expression showed variable effect on PC3 and DU145 cell proliferation. FRG1 levels consistently affected cell migration and invasion, in both DU145 and PC3 cells. Ectopic expression of FRG1 led to significant reduction in cell migration and invasion in both DU145 and PC3 cells, reverse trends were observed with FRG1 knockdown. In androgen receptor positive cell line LNCaP, FRG1 doesn't affect any of the cell properties. FRG1 knockdown led to significantly enhanced expression of GM-CSF, MMP1, PDGFA and CXCL1, in PC3 cells and, in DU145, it led to higher expression of GM-CSF, MMP1 and PLGF. Interestingly, FRG1 knockdown in both the cell lines led to activation of p38 MAPK. Pharmacological activation of p38 MAPK led to increase in the expression of GM-CSF and PLGF in DU145 whereas in PC3 it led to enhanced expression of GM-CSF, MMP1 and CXCL1. On the other hand, inhibition of p38 MAPK led to reduction in the expression of above mentioned cytokines.

Conclusion: FRG1 expression is reduced in prostate adenocarcinoma tissue. FRG1 expression affects migration and invasion in AR negative prostate cancer cells through known MMPs and cytokines, which may be mediated primarily via p38 MAPK activation.

Keywords: CXCL1; Cell invasion; Cell migration; FRG1; GM-CSF; Immunohistochemistry; MMP1; PLGF; Prostate cancer; p38 MAPK.

MeSH terms

  • Adenocarcinoma / pathology*
  • Aged
  • Biopsy, Large-Core Needle
  • Carcinogenesis
  • Cell Line, Tumor
  • Cell Movement*
  • Cell Proliferation
  • Cohort Studies
  • Disease Progression
  • Gene Expression Regulation, Neoplastic
  • Gene Knockdown Techniques
  • Humans
  • MAP Kinase Signaling System
  • Male
  • Microfilament Proteins
  • Middle Aged
  • Neoplasm Invasiveness / pathology
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism*
  • Prostate / pathology
  • Prostatic Neoplasms / pathology*
  • RNA, Small Interfering / metabolism
  • RNA-Binding Proteins
  • Receptors, Androgen / metabolism

Substances

  • AR protein, human
  • FRG1 protein, human
  • Microfilament Proteins
  • Nuclear Proteins
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • Receptors, Androgen